PeptiDream

4587.TPharmaceutical
Financials · Standalone

From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 8
PeriodFormFiledFigures
2024-01-01 → 2024-03-31Quarterly Q12024-05-1591 figures · EDINET
2023-01-01 → 2023-09-30Quarterly Q32023-11-10115 figures · EDINET
2023-01-01 → 2023-06-30Quarterly Q2Amended2023-11-09115 figures · EDINET
2023-01-01 → 2023-03-31Quarterly Q1Amended2023-11-0988 figures · EDINET
2023-01-01 → 2023-06-30Quarterly Q22023-08-10115 figures · EDINET
2023-01-01 → 2023-03-31Quarterly Q12023-05-1288 figures · EDINET
2022-01-01 → 2022-09-30Quarterly Q32022-11-11117 figures · EDINET
2022-01-01 → 2022-06-30Quarterly Q22022-08-10117 figures · EDINET

23 more reports are still being processed.

Segments · FY ended 2025-12
SegmentExternal salesProfit
Drug Discovery And Development Business¥2.8bn−¥5.4bn
Radiopharmaceuticals Business¥15.7bn¥435m
Adjustments & eliminations——
Total¥18.5bn−¥4.9bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.